Oftalmología Susceptibilidad in vitro de la flora bacteriana ocular preoperatoria a 4 Fluoroquinolonas
Referencias
1. Miño de Kaspar H, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial
flora in patients undergoing glaucoma or cataract surgery. J Glaucoma.
2004;13(6):507-9.
2. Shiff FS. The shouting
surgeons as a possible source of endophthalmitis. Ophthalmic Surg 1990; 21:
438-440.
3. Kattan HM, Flynn HW,
Plugfelder SC, Robertson C, Forster RK. Nosocomial endophthalmitis Survey.
Current incidence of infection after intraocular surgery. Ophthalmol 1991; 98:
227-238
4. Park SH, Lim JA, Choi JS, Kim
KA, Joo CK. The resistance patterns of normal ocular bacterial flora to 4
fluoroquinolone antibiotics. Cornea 2009; 28: 68-72.
5. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute Endophthalmitis in eyes treated prophylactically
with Gatifloxacin and Moxifloxacin. Am J Ophthalmol 2006;142:721-725.
6. Mather R, Karenchak L,
Romanowski E, Kowalski R. Fourth generation fluoroquinolones: New weapons in
the arsenal of ophthalmic antibiotics.Am J Ophthalmol 2002; 133: 463-466.
7. Miño de Kaspar H, Koss MJ, He
L, Blumenkranz M, N.Ta C. Antibiotic susceptibility of preoperative normal
conjunctival bacteria. Am J Ophthalmol 2005; 139: 730-733.
8. MacMahon B., Trichopoulos D.
Epidemiology: Principles and Methods. 2nd ed. Boston: Lippincott Williams & Wilkins;
1996.
9. Kowalski R, Yates K,
Romanowski E, Karenchak L, Mah F, Gordon Y. An Ophthalmologist"™s Guide to
Understanding Antibiotic Susceptibility and Minimum Inhibitory Concentration
Data. Ophthalmology 2005; 112: 1987-1991.
10. Clinical and Laboratory
Standards Institute. 2007. M100-S17. Performance standards for antimicrobial
susceptibility testing; 16th informational supplement. Clinical and Laboratory
Standards Institute, Wayne, PA.
11. New Technologies for
Infection Diagnosis and Control Impacts of Antibiotic Resistant Bacteria.
Office of Technology Assessment Congress of the United State. OTA-H-629
(Washington DC, US Government Printing Office, September 1995).
12. Yamada M, Hatou S, Yoshida J.
In vitro susceptibilities of bacterial isolates from conjunctival flora to
gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin. Eye Contact Lens.
2008 Mar;34(2):109-12.
13. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic
isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996; 122:
1-17.
14. Puliafito CA, Baker AS, Haaf
J, Foster CS. Infectious endophthalmitis. Review of 36 cases. Ophthalmol 1982;
89: 921-929.
15. Wilson FM. Causes and
prevention of endophthalmitis. Int Ophthalmol Clin 1987; 27: 67-73.
16. Koss MJ, Eder M, Blumenkranz
MS, et al.The effectiveness of the new fluoroquinolones against the normal
bacterial flora of the conjunctiva Ophthalmologe. 2007;104:21-27.
17. Solomon R, Donnenfeld ED,
Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%,
moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmol
2005;112:466-469.
18. Mather R, Karenchak LM,
Romanowski EG et al. Fourth generation fluoroquinolones: new weapons in the
arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-466.
19. Kowalski RP, Dhaliwal DK,
Krenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility
comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial
keratitis isolates. Am J Ophthalmol 2003;136:500-505.
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit